Evidence map›Paper›PMID 35378080›Full record

ArticleBiophysical journal2022

Modeling insights into SARS-CoV-2 respiratory tract infections prior to immune protection.

Alexander Chen, Timothy Wessler, Katherine Daftari, Kameryn Hinton, Richard C Boucher, Raymond Pickles, Ronit Freeman, Samuel K Lai, M Gregory Forest

Abstract read
In one paragraph

Article in Biophysical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Spatially structured models of viral dynamics: a scoping review.Microbiology and molecular biology reviews : MMBR · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander ChenDepartment of Mathematics, CSU Dominguez Hills, Carson, California.
Timothy WesslerDepartment of Mathematics, UNC Chapel Hill, Chapel Hill, North Carolina. Electronic address: tswessler@gmail.com.
Katherine DaftariDepartment of Mathematics, UNC Chapel Hill, Chapel Hill, North Carolina.
Kameryn HintonDepartment of Applied Physical Sciences, UNC Chapel Hill, Chapel Hill, North Carolina.
Richard C BoucherMarsico Lung Institute, UNC Chapel Hill, Chapel Hill, North Carolina.
Raymond PicklesMarsico Lung Institute, UNC Chapel Hill, Chapel Hill, North Carolina; Department of Microbiology and Immunology, UNC Chapel Hill, Chapel Hill, North Carolina.
Ronit FreemanDepartment of Applied Physical Sciences, UNC Chapel Hill, Chapel Hill, North Carolina.
Samuel K LaiDepartment of Microbiology and Immunology, UNC Chapel Hill, Chapel Hill, North Carolina; Joint Department of Biomedical Engineering, UNC Chapel Hill and NC State University, Chapel Hill and Raleigh, North Carolina; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC Chapel Hill, Chapel Hill, North Carolina.
M Gregory ForestDepartment of Mathematics, UNC Chapel Hill, Chapel Hill, North Carolina; Department of Applied Physical Sciences, UNC Chapel Hill, Chapel Hill, North Carolina; Joint Department of Biomedical Engineering, UNC Chapel Hill and NC State University, Chapel Hill and Raleigh, North Carolina. Electronic address: forest@unc.edu.

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Martina Gentzsch · 2004 to 2026
$26.5M
The Biophysics of Mucus Hydration and Adhesion/CohesionP01HL108808 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUBINSTEIN, MICHAEL · 2012 to 2021
$23.9M
Synthesis of Effective and Safe Mucolytics for Pulmonary DiseaseUH3HL123645 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2016 to 2018
$4.6M
Multiscale Biochemical/Biophysical Integration of Pulmonary Mucus TransportR01HL136961 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2017 to 2020
$3.2M
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPVR44AI157661 · NIAID · MUCOMMUNE, LLC · PI CONE, RICHARD · 2021 to 2024
$2.4M
Aerosol immunotherapy for treatment of human metapneumovirus infectionR43AI149894 · NIAID · MUCOMMUNE, LLC · PI CONE, RICHARD · 2020 to 2020
$262k
NCATS NIH HHS UL1 TR002489NHLBI NIH HHS P01 HL108808NHLBI NIH HHS R01 HL136961NHLBI NIH HHS UH3 HL123645NIAID NIH HHS R43 AI149894NIAID NIH HHS R44 AI157661NIDDK NIH HHS P30 DK065988
6 · The paper itself

Abstract

Mechanistic insights into human respiratory tract (RT) infections from SARS-CoV-2 can inform public awareness as well as guide medical prevention and treatment for COVID-19 disease. Yet the complexity of the RT and the inability to access diverse regions pose fundamental roadblocks to evaluation of potential mechanisms for the onset and progression of infection (and transmission). We present a model that incorporates detailed RT anatomy and physiology, including airway geometry, physical dimensions, thicknesses of airway surface liquids (ASLs), and mucus layer transport by cilia. The model further incorporates SARS-CoV-2 diffusivity in ASLs and best-known data for epithelial cell infection probabilities, and, once infected, duration of eclipse and replication phases, and replication rate of infectious virions. We apply this baseline model in the absence of immune protection to explore immediate, short-term outcomes from novel SARS-CoV-2 depositions onto the air-ASL interface. For each RT location, we compute probability to clear versus infect; per infected cell, we compute dynamics of viral load and cell infection. Results reveal that nasal infections are highly likely within 1-2 days from minimal exposure, and alveolar pneumonia occurs only if infectious virions are deposited directly into alveolar ducts and sacs, not via retrograde propagation to the deep lung. Furthermore, to infect just 1% of the 140 m

Indexed as

COVID-19AerosolsHumansLungSARS-CoV-2Viral LoadAerosols

Identifiers

PMID35378080
PMCPMC8975607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.